Covid-19 vaccines returned up to $64.3 trillion — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- PLOS Medicine published a reanalysis estimating that $79.4 billion invested in developing Covid-19 vaccines produced $6.43 trillion to $64.3 trillion in first-year global benefits, versus a preprint range of $4.8 trillion to $37.9 trillion—$59.70 to $809 per $1 invested.
- Covid-19 vaccine modeling estimated that vaccination prevented 14 million to 20 million deaths in the first year; the wider analyses cover 173 countries and include averted hospitalizations, productivity losses and lives saved.
- Value of Statistical Life replaced Value of Statistical Life Years during peer review, with Mark Jit saying the change treats life spans more equally and aligns with recommendations for valuing mortality-risk reductions.
- The $64.3 trillion public-sector cost-benefit estimate rose significantly after researchers changed how they calculated the economic value of avoiding a death; the $6.43 trillion health-sector cost-effectiveness estimate factors in quality of life.
- Vaccine returns were highest in richer countries and probably lower elsewhere because poorer countries accessed vaccines later, with fewer lives saved and fewer productivity and healthcare costs averted; Mark Jit called for fair global distribution.
- Richard Carpiano said the analysis reinforces that protecting public health protects the economy, challenging the “black-and-white” pandemic tradeoff between lockdowns and economic protection.
Why it matters: Poorer countries recorded smaller returns because access came later, while richer countries posted the highest gains from lives saved and productivity and healthcare costs averted. Against the $79.4 billion development investment, that uneven payoff makes timely, equitable vaccine distribution a concrete policy issue for future outbreaks.
Ask SkimNews
